On June 28, 2016, Jiu'an Medical intends to raise funds of not more than 710 million yuan through non-public offering of shares to acquire French eDevice company for 93,884,347 euros. Upon completion of the transaction, Jiu'an Europe will acquire 100% of the equity of eDevice held by the counterparty in cash. After I learned the news, I organized the content report.
eDevice's core business: mobile medical + data transmission
It is reported that the eNode, the target company of this transaction, was founded in 2000 and is the world's leading provider of medical equipment data information system solutions. At the beginning of its creation, eDevice focused on the development of IoT products. After a period of development, based on its own hardware and software advantages in network communications, since 2007, eDevice has begun to enter the mobile medical industry and launched its core product WireX series.
.png)
WireX series products provide customers with medical device data system solutions, which are dedicated to the large-scale medical device manufacturers and medical service organizations to solve the problem of extracting, transmitting and remotely monitoring the patient's vital signs in an efficient, stable, safe and encrypted manner. The number of devices that the company has used by end users has reached 350,000 units.
eDevice's profitability in recent years:
.png)
eDevice's main business is divided into two categories, namely, sales of mobile medical products and medical data transmission and communication services for customers.
Tiamulin Fumarate Soluble Powder
Tiamulin Powder,Tiamulin Soluble Powder,Tiamulin Hydrogen Fumarate Powder,Tiamulin Animal Drug
Shandong Shengli Bioengineering Co., Ltd , https://www.shenglipharm.com